New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - trametinib dimethyl sulfoxide 0.5635mg equivalent to trametinib 0.5 mg;   - film coated tablet - 0.5 mg - active: trametinib dimethyl sulfoxide 0.5635mg equivalent to trametinib 0.5 mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose magnesium stearate mannitol microcrystalline cellulose opadry yellow 03b120006 purified water sodium laurilsulfate - mekinist in combination with dabrafenib is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma. mekinist as a monotherapy is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma and in whom either there is an intolerance to braf inhibitors or braf inhibitors cannot be used. mekinist as monotherapy has not demonstrated clinical activity in patients who have progressed on braf inhibitor therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - trametinib dimethyl sulfoxide 2.254mg equivalent to trametinib 2 mg;   - film coated tablet - 2 mg - active: trametinib dimethyl sulfoxide 2.254mg equivalent to trametinib 2 mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose magnesium stearate mannitol microcrystalline cellulose opadry pink ys-1-14762-a purified water sodium laurilsulfate - mekinist in combination with dabrafenib is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma. mekinist as a monotherapy is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma and in whom either there is an intolerance to braf inhibitors or braf inhibitors cannot be used. mekinist as monotherapy has not demonstrated clinical activity in patients who have progressed on braf inhibitor therapy.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - acetamiprid; dimethyl sulfoxide - soluble concentrate - acetamiprid pyridine active 200.0 g/l; dimethyl sulfoxide solvent other 505.0 g/l - insecticide - cotton - cotton aphid | green mirid bug | melon aphid

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - acetamiprid; n-methyl-2-pyrrolidone; dimethyl sulfoxide - soluble concentrate - acetamiprid pyridine active 225.0 g/l; n-methyl-2-pyrrolidone solvent other 334.0 g/l; dimethyl sulfoxide solvent other 515.0 g/l - insecticide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nippon soda co., ltd - acetamiprid; n-methylpyrrolidone; dimethyl sulfoxide - soluble concentrate - acetamiprid pyridine active 225.0 g/l; n-methylpyrrolidone solvent other 334.0 g/l; dimethyl sulfoxide solvent other 515.0 g/l - insecticide - cotton | potato - cotton aphid | green mirid bug | green peach aphid | melon aphid

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - flumethasone; dimethyl sulfoxide - topical cream, ointment, paste, gel, lotion - flumethasone steroid-glucocorticoid active 0.05 mg/g; dimethyl sulfoxide solvent active 600.0 mg/g - musculoskeletal system - cat | dog | horse | bitch | castrate | cat - queen | cat - tom | colt | donkey | endurance horse | filly | foal | gelding | high - musculoskeletal conditions | arthritis | arthrosis | bursitis | external myopathy | inflamation of soft tissues an | osteitis | osteoarthritis | tendon and ligament sprains | tendonitis | tenosynovitis | traumatic joint and connective

Israel - English - Ministry of Health

novartis israel ltd - trametinib as dimethyl sulfoxide - film coated tablets - trametinib as dimethyl sulfoxide 0.5 mg - trametinib - trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy. non-small cell lung cancer (nsclc) :trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.adjuvant treatment of melanoma :trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection.braf v600e mutation-positive locally advanced or metastatic anaplastic thyroid cancertafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment optionsbraf v600e mutation-positive unresectable or metastatic solid tumorsmekinist is indicated, in combination with dabrafenib, for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. limitations of use: trametinib is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to braf inhibitiontrametinib is indicated, in combination with dabrafenib, for the treatment of pediatric patients 6 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy

Israel - English - Ministry of Health

novartis israel ltd - trametinib as dimethyl sulfoxide - film coated tablets - trametinib as dimethyl sulfoxide 2 mg - trametinib - trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy. non-small cell lung cancer (nsclc) :trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.adjuvant treatment of melanoma :trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection.braf v600e mutation-positive locally advanced or metastatic anaplastic thyroid cancertafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment optionsbraf v600e mutation-positive unresectable or metastatic solid tumorsmekinist is indicated, in combination with dabrafenib, for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. limitations of use: trametinib is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to braf inhibitiontrametinib is indicated, in combination with dabrafenib, for the treatment of pediatric patients 6 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy

Canada - English - Health Canada

accord healthcare inc - dimethyl fumarate - capsule (delayed release) - 120mg - dimethyl fumarate 120mg - immunomodulatory agents

Canada - English - Health Canada

accord healthcare inc - dimethyl fumarate - capsule (delayed release) - 240mg - dimethyl fumarate 240mg - miscellaneous central nervous system agents